Publications

Debio 1143, an oral antagonist of the inhibitor of apoptosis proteins, synergistically enhances the effects of multiple standard of care…

FGFR genetic alterations as a potential predictor of the sensitivity to CH5183284/Debio 1347, a selective FGFR inhibitor with a novel…

Activity of IAP antagonist Debio 1143 as a monotherapy and in combination with standard of care agents in models of…

A simplified and Reliable Capillary Microsampling Procedure to Support Preclinical Regulatory Studies in Rodents

A drug combination screen identifies taxanes as synergistic agents with the oral IAP inhibitor Debio 1143 in non-small cell lung…

Preclinical rationale for combining the Smac-mimetic Debio 1143 with concurrent chemioradiotherapy in LA-SCCHN

A Phase I-II evaluation of the safety and efficacy of the oral HSP90 inhibitor Debio 0932 in combination with Standard…

The cyclophilin inhibitor alisporivir prevents hepatitis C virus–mediated mitochondrial dysfunction

Debio-025 is more effective than prednisone in reducing muscular pathology in mdx mice